Dr. Yupei Chen 陈雨沛
Chief Physician
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Molecular subtyping and precision treatment strategies for nasopharyngeal carcinoma.
Dr. Chen is a Chief Physician, Researcher, and Doctoral Supervisor in the Department of Radiation Oncology. Research focuses on metastasis mechanisms and precision treatment for nasopharyngeal carcinoma. Published first or corresponding author papers in The Lancet (3), Annals of Oncology (2), Cell Research, and JCO. Recognized by MIT Technology Review Asia-Pacific "35 Innovators Under 35" and listed in Elsevier’s top 2% scientists (2023, 2024).
Professional roles
- Member, NCI Nasopharyngeal Carcinoma Clinical Trial Collaborative Group
- Member, CSCO-ASCO Joint Guideline Expert Panel for Nasopharyngeal Carcinoma
Name order: in Chinese the family name comes first (Chen Yupei). Papers usually list the name as Yupei Chen or Chen Y.
Selected publications
91 papers on PubMed matched by name and affiliation; 18 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Clin Oncol, 2026 (first author): Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update. PubMed 43008242
- Nat Cancer, 2026 (senior author): Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study. PubMed 42380630
- Med, 2025 (senior author): Association of anti-PD-1 therapy with severe radiation-induced oral mucositis: A retrospective cohort study and validation in the CONTINUUM trial. PubMed 40651471
- Sci Adv, 2023 (senior author): TEAD4 is a master regulator of high-risk nasopharyngeal carcinoma. PubMed 36608137
- Adv Sci (Weinh), 2022 (senior author): N(6) -Methyladenosine-Modified CBX1 Regulates Nasopharyngeal Carcinoma Progression Through Heterochromatin Formation and STAT1 Activation. PubMed 36310139
- Cancer Commun (Lond), 2022 (first author): Low-dose metronomic chemotherapy improves tumor control in nasopharyngeal carcinoma. PubMed 35924896
- Lancet, 2021 (first author): Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. PubMed 34111416
- J Clin Oncol, 2021 (first author): Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. PubMed 33405943
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion